Lifesci Capital upgraded shares of GlycoMimetics (NASDAQ:CBIO – Free Report) to a strong-buy rating in a research report sent to investors on Wednesday, MarketBeat.com reports. They currently have $22.00 price objective on the biopharmaceutical company’s stock.
GlycoMimetics Stock Performance
Shares of CBIO stock opened at $15.00 on Wednesday. GlycoMimetics has a 52 week low of $11.06 and a 52 week high of $63.00.
GlycoMimetics Company Profile
Featured Articles
- Five stocks we like better than GlycoMimetics
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- New All-Time Highs Coming for Broadcom? Wall Street Says Yes
- Should You Invest in Penny Stocks?
- Overheated Market? Analysts Watch These Red Flags
- What is MarketRank™? How to Use it
- 3 Reasons AMD Could Be the Hottest Stock of the Summer
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.
